# Incyte

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/incyte/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | American pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320317544 |
| ROR ID | https://ror.org/00cvzzg84 |
| Works | 5,877 |

## Funder papers

- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed/)
- [Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database](https://scholariq.org/papers/costs-and-treatment-patterns-among-patients-with-atopic-dermatitis-using/)
- [Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy](https://scholariq.org/papers/small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-dll3/)
- [Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study](https://scholariq.org/papers/long-term-effectiveness-of-dupilumab-in-patients-with-atopic-dermatitis-results/)
- [Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/efficacy-and-safety-of-niraparib-in-patients-aged-65-years-and-older-with/)
- [ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors](https://scholariq.org/papers/araf-amplification-in-small-cell-lung-cancer-transformed-tumors-following/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.